Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
0.6510
-0.0219 (-3.25%)
At close: Apr 1, 2025, 4:00 PM
0.6700
+0.0190 (2.92%)
After-hours: Apr 1, 2025, 4:31 PM EDT
Atossa Therapeutics Employees
Atossa Therapeutics had 15 employees as of December 31, 2024. The number of employees increased by 3 or 25.00% compared to the previous year.
Employees
15
Change (1Y)
3
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,700,267
Market Cap
84.09M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ATOS News
- 7 days ago - Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 12 days ago - Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 21 days ago - Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications - GlobeNewsWire
- 7 weeks ago - Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - GlobeNewsWire
- 2 months ago - Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. - GlobeNewsWire
- 2 months ago - Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 - GlobeNewsWire
- 3 months ago - Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire